CD8A and esophageal squamous cell carcinoma: The increase in CD8+ T cells proportion was observed in 14 ESCC patients in the responder group (20 cases, 70%) after neoadjuvant therapy, and only 5 in 11 cases (45%) in the non‐responder group (Figure 1C).